Administering [177Lu] Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1/2 …
Background High-risk localised prostate cancer (HRCaP) has high rates of biochemical
recurrence;[177 Lu] Lu-PSMA-617 is effective in men with advanced prostate cancer …
recurrence;[177 Lu] Lu-PSMA-617 is effective in men with advanced prostate cancer …
Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naïve patients, phase I study …
ECA van der Sar, AJAT Braat… - BMC cancer, 2023 - Springer
Background Prostate cancer patients with locoregional lymph node disease at diagnosis
(N1M0) still have a limited prognosis despite the improvements provided by aggressive …
(N1M0) still have a limited prognosis despite the improvements provided by aggressive …
Clinical trial protocol for LuTectomy: a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to prostatectomy
N Dhiantravan, J Violet, R Eapen, O Alghazo… - European urology …, 2021 - Elsevier
Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential
Benefit of 177Lu-PSMA-617 Prior to Prostatectomy - ScienceDirect Skip to main contentSkip to …
Benefit of 177Lu-PSMA-617 Prior to Prostatectomy - ScienceDirect Skip to main contentSkip to …
Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic …
177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
disorder and new effective therapeutic agents that improve patient outcomes are urgently …
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
SMB Peters, BM Privé, M de Bakker, F de Lange… - European journal of …, 2022 - Springer
Abstract Introduction While [177 Lu] Lu-PSMA radioligand therapy is currently only applied
in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low …
in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low …
Lu177‐PSMA therapy for men with advanced prostate cancer: initial 18 months experience at a single Australian tertiary institution
R McBean, B O'Kane, R Parsons… - Journal of medical …, 2019 - Wiley Online Library
Abstract Introduction Lutetium‐177‐PSMA (Lu PSMA) is a targeted systemic radioligand
treatment for metastatic castration‐resistant prostate cancer (mCRPC). Lu PSMA is …
treatment for metastatic castration‐resistant prostate cancer (mCRPC). Lu PSMA is …
First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
J Zang, X Fan, H Wang, Q Liu, J Wang, H Li, F Li… - European journal of …, 2019 - Springer
Purpose This translational study is designed to assess the safety, dosimetry and therapeutic
response to a single, low-dose of 177 Lu-EB-PSMA-617 in comparison to 177 Lu-PSMA-617 …
response to a single, low-dose of 177 Lu-EB-PSMA-617 in comparison to 177 Lu-PSMA-617 …
Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study
BM Privé, SMB Peters, CHJ Muselaers, IM van Oort… - Clinical Cancer …, 2021 - AACR
Abstract Purpose:[177Lu] Lu-PSMA-617 radioligand therapy (177Lu-PSMA) is a novel
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be …
treatment for metastatic castration-resistant prostate cancer (mCRPC), which could also be …
PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617
C Kratochwil, FL Giesel, M Stefanova… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy
of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long …
of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long …